EPB41L4A

Across TCGA pan-cancer cohorts, EPB41L4A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPB41L4A data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EPB41L4A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPB41L4A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where EPB41L4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.960	0.216	.002	27	view →
LSCC	OS	Tertile	All	0.618	0.884	.019	10	view →
LUAD	DFS	Quartile	III,IV	0.183	0.780	.006	9	view →
PDAC	DFS	Median	II,III,IV	0.289	0.593	.017	5	view →
GBM	DFS	Tertile	All	0.529	0.242	.033	2	view →
UCEC	DFS	Median	All	0.761	0.935	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPB41L4A–CCRCC (DFS)

Open the CCRCC breakdown →